Dr. Otello Stampacchia, Ph.D., is a Director on Gossamer Bio’s Board of Directors. He currently serves as a Managing Partner at Omega Funds, which he founded in 2004. He has been involved in various advisory activities in biotechnology since 2001. He has had particular recent involvement in investments in Micromet, BioVex, Juno and Jounce Therapeutics. Prior to Omega, he was Partner and served as Head of Life Sciences at AlpInvest Partners B.V., he was responsible for the direct life sciences investments, as well as assisting in due diligence for healthcare venture fund of funds investments. Before AlpInvest, he served as the Portfolio Manager of the Lombard Odier Immunology Fund. Prior to Lombard Odier, he served as a Member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and NY offices). Before joining Goldman, he helped co-found the healthcare investment activities at Index Ventures.
Otello is currently serving as or was a Director, or otherwise principal investment manager in Juno Therapeutics (acquired by Celgene), Kronos Bio, Translate Bio, Trevi Pharmaceuticals, Paratek Pharmaceuticals (public), Replimune, Morphic Therapeutics, Andrew Alliance, Achaogen (public), Intarcia Therapeutics, Fibrogen (public), Micromet (acquired by Amgen), BioVex (acquired by Amgen), CryoCath (acquired by Medtronic), CropDesign (acquired by BASF), and ExonHit Therapeutics (public).
He has a Ph.D. degree in Molecular Biology from the University of Geneva and a European Ph.D. in Biotechnology (EDBT) from the European Association for Higher Education in Biotechnology. He has an MS in Genetics from Universita’ degli Studi di Pavia.